Glow Of Hope: IISc Researchers Develop Low-Cost Probe For Early Detection Of Liver Cancer
Using a rare earth metal, the team developed a simple, affordable method to detect enzymes linked to liver cancer, a breakthrough built on a decade of dedicated work
Researchers at the Indian Institute of Science (IISc), Bengaluru, have developed an innovative and affordable luminescent probe that uses terbium—a rare earth metal—to help in early detection of liver cancer. The breakthrough built on a decade of dedicated work is significant because it offers a low-cost, accessible way to detect enzymes linked to liver cancer.
Unlike traditional methods that require extensive, high-end equipment, the new technique uses a simple UV lamp and free, open-source software, ImageJ, to analyse results. This makes it especially valuable for use in resource-limited settings, where access to advanced lab tools may be a problem.
'Conventional methods of colour-based testing and fluorescence for detecting such enzymes linked to liver cancer often struggle with low sensitivity or interference from background signals. But the ability of rare earth metals to have long-lived excited state allows us to filter out short-lived background fluorescence, resulting in a much clearer signal," explained Ananya Biswas, former PhD student at IISc and co-first author of the paper published in peer-reviewed journal Chemistry.
To make the test easy, the team designed this assay as a simple paper-based sensor. While clinical studies are still needed to validate the assay, the team is hopeful that such sensors could significantly lower the cost of detecting clinically-significant biomarkers.
10 YEARS OF DEDICATED WORK
So, almost a decade ago, the team began conducting experiments on metal ions and their gel-forming properties, and found that terbium ions placed in a gel made from bile salts can emit green fluorescence. The researchers then added an organic molecule called 2,3-DHN (2,3-Dihydroxynaphthalene) which was covered with a layer of glucuronic acid and shined UV light on the sample to see the results.
'The free 2,3-DHN acts as an 'antenna', absorbing UV light and transferring the energy to the nearby terbium ions, making them glow brighter. The gel keeps the antenna and terbium ions close together, so the energy transfer works well," explained corresponding author Uday Maitra, honorary professor in the department of organic chemistry, IISc.
Furthermore, the researchers highlighted that using this method, they were able to detect the enzyme at levels as low as 185 ng/mL. To put this in perspective, β-glucuronidase levels of around 1,000 ng/mL are typically seen in people with decompensated cirrhosis, an advanced stage of liver disease, so their method can help in early detection.
'With liver cancer claiming more lives each year, such a technological advance is both timely and promising. Given the wide clinical relevance of β-glucuronidase as a biomarker in different types of cancers, neonatal jaundice, and NSAID-induced toxicity, this sensor offers a potentially powerful screening tool," the team added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
13 hours ago
- Hans India
IISc develops simple sensor for detecting liver cancer
Researchers at the Indian Institute of Science (IISc) Bangalore have developed a simple sensor that is cost-effective and can enable faster detection of liver cancer. The team focussed on the potential of terbium -- a rare earth metal -- to develop a unique luminescent probe that can sense the presence of an enzyme called beta-glucuronidase. While its core function is to break down a sugar acid called glucuronic acid, the enzyme also doubles as a critical biomarker for liver cancer. An increase in beta-glucuronidase levels has been associated with the risk of colon, breast, and renal cancers, as well as infections of the urinary tract and AIDS. Thus, the novel sensor offers a potentially powerful screening tool against different types of cancers, neonatal jaundice, and NSAID-induced toxicity, said the researchers. 'Conventional methods of colorimetry and fluorescence for detecting such enzymes are often restricted by sensitivity or interference from background signals. The ability of rare earth metals to have long-lived excited states allows us to filter out short-lived background fluorescence, resulting in a much clearer signal,' said Ananya Biswas, former PhD student at IISc and co-first author of the paper published in the journal Chemistry. The innovation began with research into the gel-forming properties of metal ions. The IISC team discovered that terbium ions, when incorporated into a gel matrix derived from bile salts, emitted a bright green glow. To this, the researchers added a molecule called 2,3-DHN ((2,3-Dihydroxynaphthalene), masked with glucuronic acid. In the presence of beta-glucuronidase, terbium ions cleave the mask, releasing 2,3-DHN, which then acts as an 'antenna,' absorbing UV light. It also transfers energy to nearby terbium ions, amplifying the green fluorescence, explained Uday Maitra, Professor in the Department of Organic Chemistry, IISc. Further, to make the technology accessible, the team embedded the gel matrix onto paper discs, creating a simple and portable sensor. Exposing the samples containing beta-glucuronidase, these discs emitted a pronounced green glow under UV light. These sensors could also be analysed using a UV lamp and ImageJ -- an open source, freely accessible software, making this technique ideal for resource-limited settings, the team said. The sensor showed a detection limit, which was significantly below the beta-glucuronidase levels typically seen for cirrhosis -- an advanced stage of liver disease. While more clinical studies are needed to validate the findings, such sensors can bring down the cost of detecting clinically significant biomarkers, the researchers said.
The Hindu
20 hours ago
- The Hindu
A new BHARAT- establishing baseline health parameters for the Indian population
We don't all age the same way, but we all do age. We intuitively recognise frailty when things start to slow down. Ageing unfolds at different rates, over time, between individuals, within and across populations. Often, it happens in bursts. Ageing is complicated. It is driven by molecular and cellular interactions and is shaped by one's environment, lifestyle, and socioeconomic conditions. This means one's chronological age often doesn't reflect how old one's body really is. Since researchers discovered in 1935 that ageing can be altered, they have been looking for reliable biological clues, called biomarkers, that in isolation or together can indicate how old our bodies are and how they might respond to factors such as diet, exercise, etc. Biomarkers of ageing Last year, the Indian Institute of Science (IISc), Bengaluru, launched a large-scale study called BHARAT, short for 'Biomarkers of Healthy Aging, Resilience, Adversity, and Transitions', as part of its Longevity India Program. The study aims to map the physiological, molecular, and environmental indicators that drive ageing in the Indian population. 'We lack clear information on what features define or influence healthy ageing,' says Deepak Kumar Saini, convener of BHARAT and professor of development biology and genetics at IISc. 'We are building an information portal to understand the rules of healthy ageing in Indians.' Worldwide, life expectancy has risen significantly over the past few decades. In India it climbed 4.1 years to 67.3 in the first two decades of this century. Living longer doesn't mean living healthier, however. Studies have predicted a 168% increase in Parkinson's disease cases in India by 2050 and a 200% rise in dementia across low- and middle-income countries. Yet much of what we know about health and disease risk comes from studies in Western populations, which means the diagnostic tools, biomarkers, and even treatments may not be optimal for people in India or other non-Western countries. Gaps for patients in Global South This limited focus has created a gap between population-based biomarkers and diagnostic cut-offs for people in the Global South. This can lead to misdiagnosis and treatments that don't reflect how diseases progress or respond to therapeutics in different groups. 'Western values for cholesterol, vitamin D, or B12 may label many Indians as deficient. But are these truly abnormal within our context? Our study aims to answer that. We are not only identifying biomarkers for healthy ageing but also building the Bharat Baseline — a reliable reference for what is normal in the Indian population,' Prof. Saini says. Earlier this year, researchers from Sichuan, China, reported in Scientific Reports that certain biomarkers for breast cancer, such as high levels of high-density lipoprotein cholesterol, could signal an elevated risk in European populations but may serve as supportive indicators in Asians. 'We see differences in inflammatory markers. For instance, C-reactive protein (CRP) levels tend to be elevated in Indians even without acute illness. This inflammation often results from early-life infections, environmental toxins, or chronic nutritional and metabolic issues,' Shawn T. Joseph, senior consultant, head and neck surgical oncology, VPS Lakeshore Hospital in Kochi, says. 'Applying Western CRP cut-offs risks missing early warning signs of cardiovascular or metabolic disease in Indian patients,' he adds. An India-specific database BHARAT's goal is to change this. Its database will include genomic biomarkers (like mutations linked to disease susceptibility), proteomic and metabolic indicators (reflecting biological pathways and metabolic health), and environmental and lifestyle factors. Identifying early warning signs of age-related changes can enable better prediction, intervention, and potentially delay the onset of disease. There is a need for proactive markers of health, indicators that can tell when an organ is functioning below its optimal level, even if it is not yet diseased. For instance, your liver age is more than your chronological age. To do that, researchers must sift through large, many-dimensional datasets and plan to take the help of artificial intelligence (AI) models. 'AI and machine learning are essential to integrate and analyse layered data to see the full picture. It can simulate the impact of interventions and augment existing datasets to improve signal detection that may otherwise be missed in high-dimensional, small-sample studies. This will help us choose the most effective interventions before launching costly trials,' says Tavpritesh Sethi, professor of computational biology at the Indraprastha Institute of Information Technology, Delhi, who is also one of the investigators of BHARAT. However, if the AI models' training datasets don't reflect local realities, they risk perpetuating health inequities. India's population is genetically, environmentally, and socioeconomically diverse. Capturing this diversity in a single database is crucial but also logistically complex. Prof Saini anticipates a few challenges, including the difficulty of obtaining samples from healthy adults, securing long-term government and philanthropic funding, and expanding the study to collect samples from across the country. (Rupsy Khurana is science communication and outreach lead at the National Centre for Biological Sciences, Bengaluru.
News18
a day ago
- News18
Glow Of Hope: IISc Researchers Develop Low-Cost Probe For Early Detection Of Liver Cancer
Last Updated: Using a rare earth metal, the team developed a simple, affordable method to detect enzymes linked to liver cancer, a breakthrough built on a decade of dedicated work Researchers at the Indian Institute of Science (IISc), Bengaluru, have developed an innovative and affordable luminescent probe that uses terbium—a rare earth metal—to help in early detection of liver cancer. The breakthrough built on a decade of dedicated work is significant because it offers a low-cost, accessible way to detect enzymes linked to liver cancer. Unlike traditional methods that require extensive, high-end equipment, the new technique uses a simple UV lamp and free, open-source software, ImageJ, to analyse results. This makes it especially valuable for use in resource-limited settings, where access to advanced lab tools may be a problem. 'Conventional methods of colour-based testing and fluorescence for detecting such enzymes linked to liver cancer often struggle with low sensitivity or interference from background signals. But the ability of rare earth metals to have long-lived excited state allows us to filter out short-lived background fluorescence, resulting in a much clearer signal," explained Ananya Biswas, former PhD student at IISc and co-first author of the paper published in peer-reviewed journal Chemistry. To make the test easy, the team designed this assay as a simple paper-based sensor. While clinical studies are still needed to validate the assay, the team is hopeful that such sensors could significantly lower the cost of detecting clinically-significant biomarkers. 10 YEARS OF DEDICATED WORK So, almost a decade ago, the team began conducting experiments on metal ions and their gel-forming properties, and found that terbium ions placed in a gel made from bile salts can emit green fluorescence. The researchers then added an organic molecule called 2,3-DHN (2,3-Dihydroxynaphthalene) which was covered with a layer of glucuronic acid and shined UV light on the sample to see the results. 'The free 2,3-DHN acts as an 'antenna', absorbing UV light and transferring the energy to the nearby terbium ions, making them glow brighter. The gel keeps the antenna and terbium ions close together, so the energy transfer works well," explained corresponding author Uday Maitra, honorary professor in the department of organic chemistry, IISc. Furthermore, the researchers highlighted that using this method, they were able to detect the enzyme at levels as low as 185 ng/mL. To put this in perspective, β-glucuronidase levels of around 1,000 ng/mL are typically seen in people with decompensated cirrhosis, an advanced stage of liver disease, so their method can help in early detection. 'With liver cancer claiming more lives each year, such a technological advance is both timely and promising. Given the wide clinical relevance of β-glucuronidase as a biomarker in different types of cancers, neonatal jaundice, and NSAID-induced toxicity, this sensor offers a potentially powerful screening tool," the team added.
